Van Bael & Bellis (VBB) is pleased to announce that it has appointed competition partner Andreas Reindl as its new managing partner, with effect from 1 February 2024. Andreas succeeds Philippe De Baere who has led the firm since 2016 and will continue to practise as a member of VBB’s EU and international trade law group
The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have published recommendations to tackle shortages of GLP-1 receptor agonists
On 24 June 2024, the Belgian Competition Authority (BCA) launched a public consultation regarding the draft brochure entitled “The Digital Markets Act – a short guide for tech challengers”
Sincere congratulations to our long-standing client Gedeon Richter for its acquisition of all shares in Estetra and Neuralis from Mithra Pharmaceuticals
Identification and assessment of cartel risk is an essential component of overall business risk management. In an environment where competition authorities around the world, including in the EU, are stepping up their cartel enforcement activity, it becomes an even greater strategic imperative to understand the relevant rules and ensure appropriate compliance.
Today, on 17 June 2024, the Official Journal of the European Union publishes Commission Delegated Regulation (EU) 2024/1701 of 11 March 2024 “amending Regulation (EC) No 1234/2008 as regards the examination of variations to the terms of marketing authorisations for medicinal products for human use”
The Belgian Competition Authority (BCA) published on 13 June 2024 an opinion analysing the benefits and drawbacks of a possible merger with other market regulators.
The Luxembourg Competition Authority (LCA) announced today that it carried out on-premise inspections in the life sciences sector targeting suppliers of pharmaceutical and related products (see, attached press release). In keeping with good operating practices, the LCA did not identify the firms which it visited. Likewise, it was not forthcoming with details regarding the practices which it sought to review and only referred to “anticompetitive arrangements”.
Today, the European Commission (the Commission) publicly announced that it sent a Statement of Objections to Alchem for that firm’s alleged involvement in a cartel in relation to N-Butylbromide Scopolamine/Hyoscine (SNBB), the active ingredient of the anti-cramp medicine Buscopan® and its generic versions. Earlier, the Commission had concluded a settlement agreement with the other members of the cartel which agreed to the payment of a total fine of EUR 13.4 million
The Italian competition authority (Autorità Garante della Concorrenza e del Mercato – AGCM) has decided to discontinue an investigation of 7 suppliers of radiopharmaceutical medicines.